SCHEMBL5030293

SCHEMBL5030293

CCOCc1nc2c(N)nc(C)c(C)c2n1CCNC(=O)Nc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 10/20 0.46
TLR8 Q9NR97 8/20 0.46
NUDT1 P36639 1/20 0.44
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
HSD17B10 Q99714 1/20 0.42
FAAH O00519 1/20 0.40
EPHX1 P07099 3/20 0.39
HTT P42858 1/20 0.39
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6776452 0.95 TLR7 (0.46) TLR7TLR8NUDT1ALDH1A1FAAH
SCHEMBL5750404 0.87 TLR8 (0.62) TLR7TLR8NUDT1
SCHEMBL1312806 0.87 TLR7 (0.51) TLR7TLR8NUDT1ALDH1A1KDM4E
Hydrochloric Acid SCHEMBL5032733 0.86 TLR7 (0.51) TLR7TLR8NUDT1ALDH1A1KDM4E
SCHEMBL6781852 0.86 CCR3 (0.42) TLR7KDM4E
SCHEMBL6783075 0.85 HDAC3 (0.43) TLR7TLR8NUDT1ALDH1A1GAA
SCHEMBL6777586 0.85 PKM (0.47) TLR7ALDH1A1HPGDHSD17B10HTT
SCHEMBL6776337 0.85 TLR8 (0.45) TLR7TLR8NUDT1ALDH1A1GAA
SCHEMBL6782683 0.85 MEN1 (0.44) TLR7TLR8NUDT1MEN1KMT2A
SCHEMBL6776784 0.85 ALDH1A1 (0.48) TLR7ALDH1A1KDM4EGLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312434-A1 PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-12-18 US disclosed
US-20080312434-A1 PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-12-18 US disclosed
US-20080312434-A1 PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-12-18 US disclosed
US-20050032829-A1 Process for imidazo[4,5-c]pyridin-4-amines 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 US disclosed
WO-2004110992-A2 PROCESS FOR IMIDAZO[4,5-C] PYRIDIN-4-AMINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312434-A1 PROCESS FOR IMIDAZO [4,5-C] PYRIDIN-4-AMINES PAICS, HTR4, PNPO TLR7 974/4885TLR8 1214/4885NUDT1 322/4885
US-20050032829-A1 Process for imidazo[4,5-c]pyridin-4-amines PAICS, HTR4, PNPO TLR7 974/4885TLR8 1214/4885NUDT1 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.